T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children. 2012

Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
Laboratory for Infectious Disease and Perinatal Screening, Center for Infectious Diseases Control, National Institute for Public Health, Bilthoven, The Netherlands.

Immunization with acellular pertussis vaccine (aP) induces higher specific antibody levels and fewer adverse reactions than does immunization with the whole-cell vaccine (wP). However, antibody levels in infants induced by both types of pertussis vaccines wane already after 1 year. Therefore, long-term T-cell responses upon vaccination might play a role in protection against pertussis. In a cross-sectional study (ISRCTN65428640), we investigated T-helper (Th) cell immune responses in wP- or aP-vaccinated children before and after an aP low-dose or high-dose preschool booster at 4 years of age in The Netherlands. T cells were stimulated with pertussis vaccine antigens. The numbers of gamma interferon-producing cells and Th1, Th2, Th17, and interleukin-10 (IL-10) cytokine concentrations were determined. In addition, pertussis-specific IgE levels were measured in plasma. Children being vaccinated with aP vaccinations at 2, 3, 4, and 11 months of age still showed higher pertussis-specific T-cell responses at 4 years of age than did wP-vaccinated children. These T-cell responses failed to show a typical increase in cytokine production after a fifth aP vaccination but remained high after a low-dose booster and seemed to decline even after a high-dose booster. Importantly, elevated IgE levels were induced after this booster vaccination. In contrast, wP-vaccinated children had only low prebooster T-cell responses, and these children showed a clear postbooster T-cell memory response even after a low-dose booster vaccine. Four high-dose aP vaccinations in infancy induce high T-cell responses still present even 3 years after vaccination and enhanced IgE responses after preschool booster vaccination. Therefore, studies of changes in vaccine dosage, timing of pertussis (booster) vaccinations, and the possible association with local side effects are necessary.

UI MeSH Term Description Entries
D007073 Immunoglobulin E An immunoglobulin associated with MAST CELLS. Overexpression has been associated with allergic hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). IgE
D007223 Infant A child between 1 and 23 months of age. Infants
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D010567 Pertussis Vaccine A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed) Vaccine, Pertussis
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies

Related Publications

Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
September 2014, Clinical and vaccine immunology : CVI,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
August 1999, Infection and immunity,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
September 2015, Vaccine,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
March 1998, Vaccine,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
December 2013, Vaccine,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
September 2012, The New England journal of medicine,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
January 2016, Vaccine,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
September 2017, The Pediatric infectious disease journal,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
January 2000, Pediatrics,
Rose-Minke Schure, and Lotte H Hendrikx, and Lia G H de Rond, and Kemal Oztürk, and Elisabeth A M Sanders, and Guy A M Berbers, and Anne-Marie Buisman
April 2001, The Pediatric infectious disease journal,
Copied contents to your clipboard!